Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia.

Mancini GBJ, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE.

JACC Cardiovasc Interv. 2014 Feb;7(2):195-201. doi: 10.1016/j.jcin.2013.10.017. Epub 2014 Jan 15.

2.

Ischemia change in stable coronary artery disease is an independent predictor of death and myocardial infarction.

Farzaneh-Far A, Phillips HR, Shaw LK, Starr AZ, Fiuzat M, O'Connor CM, Sastry A, Shaw LJ, Borges-Neto S.

JACC Cardiovasc Imaging. 2012 Jul;5(7):715-24. doi: 10.1016/j.jcmg.2012.01.019.

3.

Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators.

Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.

4.

Prognostic importance of coronary anatomy and left ventricular ejection fraction despite optimal therapy: assessment of residual risk in the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation Trial.

Mancini GB, Hartigan PM, Bates ER, Chaitman BR, Sedlis SP, Maron DJ, Kostuk WJ, Spertus JA, Teo KK, Dada M, Knudtson M, Berman DS, Booth DC, Boden WE, Weintraub WS.

Am Heart J. 2013 Sep;166(3):481-7. doi: 10.1016/j.ahj.2013.07.007. Epub 2013 Aug 2.

PMID:
24016497
5.

Prognostic utility of myocardial blush grade after PCI in patients with NSTE-ACS: Analysis from the ACUITY trial.

Ng VG, Lansky AJ, Toro S, Parise H, Cristea E, Mehran R, Stone GW.

Catheter Cardiovasc Interv. 2016 Aug;88(2):215-24. doi: 10.1002/ccd.25865. Epub 2015 Nov 18.

PMID:
25641255
6.

Is it form or function?: the "COURAGE" to ask.

King SB 3rd.

JACC Cardiovasc Interv. 2014 Feb;7(2):202-203. doi: 10.1016/j.jcin.2013.10.018. Epub 2014 Jan 15. No abstract available.

7.

Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.

Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, Berman DS, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Aslan M, Dada M, Boden WE, Mancini GB; Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Investigators and Coordinators.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):409-18. doi: 10.1161/CIRCOUTCOMES.113.000139. Epub 2013 Jul 9.

8.

Impact of 3-dimensional bifurcation angle on 5-year outcome of patients after percutaneous coronary intervention for left main coronary artery disease: a substudy of the SYNTAX trial (synergy between percutaneous coronary intervention with taxus and cardiac surgery).

Girasis C, Farooq V, Diletti R, Muramatsu T, Bourantas CV, Onuma Y, Holmes DR, Feldman TE, Morel MA, van Es GA, Dawkins KD, Morice MC, Serruys PW.

JACC Cardiovasc Interv. 2013 Dec;6(12):1250-60. doi: 10.1016/j.jcin.2013.08.009.

9.

Residual ischemia after revascularization in multivessel coronary artery disease: insights from measurement of absolute myocardial blood flow using magnetic resonance imaging compared with angiographic assessment.

Arnold JR, Karamitsos TD, van Gaal WJ, Testa L, Francis JM, Bhamra-Ariza P, Ali A, Selvanayagam JB, Westaby S, Sayeed R, Jerosch-Herold M, Neubauer S, Banning AP.

Circ Cardiovasc Interv. 2013 Jun;6(3):237-45. doi: 10.1161/CIRCINTERVENTIONS.112.000064. Epub 2013 May 21.

10.
11.

Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial.

Acharjee S, Teo KK, Jacobs AK, Hartigan PM, Barn K, Gosselin G, Tanguay JF, Maron DJ, Kostuk WJ, Chaitman BR, Mancini GB, Spertus JA, Dada MR, Bates ER, Booth DC, Weintraub WS, O'Rourke RA, Boden WE; COURAGE Trial Research Group.

Am Heart J. 2016 Mar;173:108-17. doi: 10.1016/j.ahj.2015.07.020. Epub 2015 Jul 26.

PMID:
26920603
12.

Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.

Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators.

J Am Coll Cardiol. 2009 Sep 29;54(14):1303-8. doi: 10.1016/j.jacc.2009.07.013.

13.

Prognostic Value of Coronary Artery Calcium Scoring in Addition to Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging in Symptomatic Patients.

Engbers EM, Timmer JR, Ottervanger JP, Mouden M, Knollema S, Jager PL.

Circ Cardiovasc Imaging. 2016 May;9(5). pii: e003966. doi: 10.1161/CIRCIMAGING.115.003966.

14.

Presence of sigma shaped right coronary artery is an indicator of poor prognosis in patients with inferior myocardial infarction treated with primary percutaneous coronary intervention.

Güngör B, Alper AT, Ozcan KS, Ekmekçi A, Karadeniz FÖ, Mutluer FO, Kaya A, Karataş B, Osmonov D, Bolca O.

Catheter Cardiovasc Interv. 2014 Nov 15;84(6):965-72. doi: 10.1002/ccd.25388. Epub 2014 Feb 12.

PMID:
24402881
15.

Rest-redistribution 201-Thallium single photon emission computed tomography predicts myocardial infarction and cardiac death in patients with ischemic left ventricular dysfunction.

Perrone-Filardi P, Pace L, Dellegrottaglie S, Corrado L, Prastaro M, Cafiero M, Caiazzo G, Marzano A, Cesarano P, Gargiulo P, Paolillo S, Maglione A, Petretta A, Chiariello M.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):122-8. doi: 10.2459/JCM.0b013e32831a0ea8.

PMID:
19377379
16.

Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).

Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators.

Am J Cardiol. 2009 Jul 1;104(1):1-4. doi: 10.1016/j.amjcard.2009.02.059. Epub 2009 Apr 16.

PMID:
19576311
17.

Left Main Stenting in Comparison With Surgical Revascularization: 10-Year Outcomes of the (Left Main Coronary Artery Stenting) LE MANS Trial.

Buszman PE, Buszman PP, Banasiewicz-Szkróbka I, Milewski KP, Żurakowski A, Orlik B, Konkolewska M, Trela B, Janas A, Martin JL, Kiesz RS, Bochenek A.

JACC Cardiovasc Interv. 2016 Feb 22;9(4):318-327. doi: 10.1016/j.jcin.2015.10.044.

18.

Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease.

Mancini GB, Farkouh ME, Brooks MM, Chaitman BR, Boden WE, Vlachos H, Hartigan PM, Siami FS, Sidhu MS, Bittner V, Frye R, Fuster V.

J Am Coll Cardiol. 2016 Sep 6;68(10):985-95. doi: 10.1016/j.jacc.2016.06.021.

19.

Improved near-term coronary artery disease risk classification with gated stress myocardial perfusion SPECT.

Shaw LJ, Wilson PW, Hachamovitch R, Hendel RC, Borges-Neto S, Berman DS.

JACC Cardiovasc Imaging. 2010 Nov;3(11):1139-48. doi: 10.1016/j.jcmg.2010.09.008.

20.

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).

Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM.

JACC Cardiovasc Interv. 2013 Jul;6(7):671-83. doi: 10.1016/j.jcin.2013.03.014.

Supplemental Content

Support Center